Venture Capital News: Gameto Closes $44M Series C Round
2025-08-12
AUSTIN, TX, Gameto, a clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health, today announced the completion of a $44 million Series C financing round.
The round was led by Overwater Ventures, with participation from Insight Partners, RA Capital, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investment Partners, PAGS Group, Pontiva Healthcare Partners, Portfolia, and additional investors.
Gameto is a women's health biotechnology company advancing programs from a cell engineering platform developed with George Church's lab at Harvard Medical School. Founded by Dr. Dina Radenkovic, a medical doctor-turned-entrepreneur, and Martin Varsavsky, founder of one of North America's largest fertility clinic network, Inception Prelude, Gameto has raised $127 million from leading investors to develop therapies that address fertility, menopause, and women's and family health. The company's lead program, Fertilo, is currently in Phase 3 clinical trials.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors